Evofem Biosciences, Inc.

Evofem Biosciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Evofem Biosciences, Inc. is not a good value stock. Evofem Biosciences, Inc. is not very popular among insiders. Evofem Biosciences, Inc. is a mediocre stock to choose.
Log in to see more information.
Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs...
EVFM Fundamental Data by TradingView

News

Evofem Biosciences Announces 1-for-125 Reverse Stock Split
Evofem Biosciences Announces 1-for-125 Reverse Stock Split

PR Newswire Evofem Biosciences Announces 1-for-125 Reverse Stock Split Evofem Biosciences Announces 1-for-125 Reverse Stock Split PR Newswire SAN DIEGO, May 17, 2023 --CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to 'EVFMD' for 20 business days...\n more…

Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

PR Newswire Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required PR Newswire SAN DIEGO, April 12, 2023 Improves Phexxi coverage for more than 5.8 million New York lives...\n more…

'Anything to survive': How one leader is pushing ahead
'Anything to survive': How one leader is pushing ahead

Fortune The CEO of Evofem Biosciences is managing through a crushing debt load, Nasdaq delisting, and sweeping layoffs. The CEO of Evofem Biosciences is managing through a crushing debt load, Nasdaq delisting, and sweeping layoffs. Read More...\n more…

Evofem Biosciences Appoints Interim Chief Financial Officer
Evofem Biosciences Appoints Interim Chief Financial Officer

PR Newswire Evofem Biosciences Appoints Interim Chief Financial Officer Evofem Biosciences Appoints Interim Chief Financial Officer PR Newswire SAN DIEGO, March 9, 2023 SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as...\n more…

Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

PR Newswire Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi PR Newswire SAN DIEGO, Feb. 27, 2023 -- Evofem now has four Orange Book listed patents covering Phexxi into...\n more…